Covid-19: a rapidly scalable SARS-Cov-2 vaccine platform based on recombinant spoke protein manufactured in insect cells using flashBAC to maximise yield and quality

保护个人免受COVID-19等冠状病毒感染的最佳验证方法是针对颗粒周围的刺突蛋白，该蛋白在细胞附着和病毒细胞进入中发挥关键作用。制造用于疫苗的刺突蛋白的最安全方法之一是使用基于只能在昆虫细胞中生长的病毒的生产系统。这种杆状病毒可以被重新编程以产生COVID-19刺突蛋白。一旦修饰的杆状病毒用于感染在生物反应器中繁殖的昆虫细胞，其导致刺突蛋白释放到支持细胞生长的液体培养基中。然后可以提取刺突蛋白，纯化，与佐剂混合并用作疫苗。这种佐剂有助于刺激接种疫苗的人的免疫力，以确保免受COVID-19的影响，并具有额外的优势，即它有助于防止可能导致肺部损伤的疫苗不良反应。随着病毒变异体的出现，我们将评估可能针对一种以上病毒变异体提供保护的多价疫苗的生产。与我们的合作伙伴Vaxine Pty Ltd（一家主要疫苗公司）合作，我们计划在18个月内生产首批COVID-19疫苗，用于第一阶段试验和优化大规模生产的工艺。

The best validated approach to protect individuals against coronaviruses such as COVID-19 is to target the spike protein that surrounds the particle and which plays a key role in cellular attachment and virus cell entry. One of the safest ways to make spike protein for use in a vaccine is to use a production system based on a virus that can only grow in insect cells. This baculovirus can be reprogrammed to make the COVID-19 spike protein. Once the modified baculovirus is used to infect insect cells propagated in bioreactors, it results in the release of the spike protein into the liquid medium supporting growth of the cells. The spike protein can then be extracted, purified, mixed with an adjuvant and used as a vaccine. The adjuvant helps to stimulate immunity in those receiving the vaccine to ensure protection from COVID-19 and has the added advantage that it helps to protect against adverse vaccine reactions that may cause damage to the lungs. With the emergence of virus variants, we will evaluate the production of a multi-valent vaccine that may protect against more than one virus variant. With our partner Vaxine Pty Ltd, a major vaccine company, we plan to have initial batches of COVID-19 vaccine produced for Phase 1 trials and processes designed for optimised large scale manufacture within 18 months.